These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 32683851)

  • 1. The expression and prognostic significance of Topo-II and c-erbB-2 in breast cancer.
    Shao H; Feng C; Wang Z; Zhu S; Zheng X
    Minerva Med; 2024 Aug; 115(4):458-464. PubMed ID: 32683851
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Human DNA topoisomerase II-alpha: a new marker of cell proliferation in invasive breast cancer.
    Lynch BJ; Guinee DG; Holden JA
    Hum Pathol; 1997 Oct; 28(10):1180-8. PubMed ID: 9343325
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predictive value of topoisomerase IIalpha and other prognostic factors for epirubicin chemotherapy in advanced breast cancer.
    Järvinen TA; Holli K; Kuukasjärvi T; Isola JJ
    Br J Cancer; 1998 Jun; 77(12):2267-73. PubMed ID: 9649144
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic significance of serum c-erbB-2 protein in breast cancer patients.
    Willsher PC; Beaver J; Pinder S; Bell JA; Ellis IO; Blamey RW; Robertson JF
    Breast Cancer Res Treat; 1996; 40(3):251-5. PubMed ID: 8883967
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Topoisomerase II alpha expression and the Ki-67 labeling index correlate with prognostic factors in estrogen receptor-positive and human epidermal growth factor type-2-negative breast cancer.
    Tokiniwa H; Horiguchi J; Takata D; Kikuchi M; Rokutanda N; Nagaoka R; Sato A; Odawara H; Tozuka K; Oyama T; Takeyoshi I
    Breast Cancer; 2012 Oct; 19(4):309-14. PubMed ID: 21725655
    [TBL] [Abstract][Full Text] [Related]  

  • 6. DNA topoisomerase II-alpha immunoreactivity as a marker of tumor aggressiveness in invasive breast cancer.
    Nakopoulou L; Lazaris AC; Kavantzas N; Alexandrou P; Athanassiadou P; Keramopoulos A; Davaris P
    Pathobiology; 2000; 68(3):137-43. PubMed ID: 11174071
    [TBL] [Abstract][Full Text] [Related]  

  • 7. c-erbB-2 oncoprotein, CEA, and CA 15.3 in patients with breast cancer: prognostic value.
    Molina R; Jo J; Filella X; Zanon G; Pahisa J; Mu noz M; Farrus B; Latre ML; Escriche C; Estape J; Ballesta AM
    Breast Cancer Res Treat; 1998 Sep; 51(2):109-19. PubMed ID: 9879773
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The predictive and prognostic significance of pre- and post-treatment topoisomerase IIα in anthracycline-based neoadjuvant chemotherapy for local advanced breast cancer.
    Chen S; Huang L; Liu Y; Chen CM; Wu J; Shao ZM
    Eur J Surg Oncol; 2013 Jun; 39(6):619-26. PubMed ID: 23473851
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Plasma c-erbB-2 levels in breast cancer patients: prognostic significance in predicting response to chemotherapy.
    Mehta RR; McDermott JH; Hieken TJ; Marler KC; Patel MK; Wild LD; Das Gupta TK
    J Clin Oncol; 1998 Jul; 16(7):2409-16. PubMed ID: 9667258
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The prognostic significance of c-erbB-2 serum protein in metastatic breast cancer.
    Fehm T; Maimonis P; Katalinic A; Jäger WH
    Oncology; 1998; 55(1):33-8. PubMed ID: 9428373
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HER-2 and topo-isomerase IIalpha as predictive markers in a population of node-positive breast cancer patients randomly treated with adjuvant CMF or epirubicin plus cyclophosphamide.
    Di Leo A; Larsimont D; Gancberg D; Jarvinen T; Beauduin M; Vindevoghel A; Michel J; Focan CH; Ries F; Gobert PH; Closon-Dejardin MT; Dolci S; Rouas G; Paesmans M; Lobelle JP; Isola J; Piccart MJ
    Ann Oncol; 2001 Aug; 12(8):1081-9. PubMed ID: 11583189
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Topoisomerase IIalpha expression in ductal carcinoma in situ of the breast: a preliminary study.
    Shpitz B; Bomstein Y; Zehavi T; Bernheim J; Liverant S; Kaufman Z; Buklan G; Klein E
    Hum Pathol; 2000 Oct; 31(10):1249-54. PubMed ID: 11070118
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Topoisomerase IIalpha expression in breast cancer: correlation with outcome variables.
    Depowski PL; Rosenthal SI; Brien TP; Stylos S; Johnson RL; Ross JS
    Mod Pathol; 2000 May; 13(5):542-7. PubMed ID: 10824926
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression of topoisomerase IIalpha is associated with rapid cell proliferation, aneuploidy, and c-erbB2 overexpression in breast cancer.
    Järvinen TA; Kononen J; Pelto-Huikko M; Isola J
    Am J Pathol; 1996 Jun; 148(6):2073-82. PubMed ID: 8669491
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Therapeutic strategies in male breast cancer: clinical implications of chromosome 17 gene alterations and molecular subtypes.
    Schildhaus HU; Schroeder L; Merkelbach-Bruse S; Binot E; Büttner R; Kuhn W; Rudlowski C
    Breast; 2013 Dec; 22(6):1066-71. PubMed ID: 24080492
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Increased Expression of c-Met is Associated with Chemotherapy-Resistant Breast Cancer and Poor Clinical Outcome.
    Jia L; Yang X; Tian W; Guo S; Huang W; Zhao W
    Med Sci Monit; 2018 Nov; 24():8239-8249. PubMed ID: 30444219
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multidrug resistance-associated biomarkers PGP, GST-pi, Topo-II and LRP as prognostic factors in primary ovarian carcinoma.
    Lu D; Shi HC; Wang ZX; Gu XW; Zeng YJ
    Br J Biomed Sci; 2011; 68(2):69-74. PubMed ID: 21706917
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Detection of urokinase plasminogen activator receptor and c-erbB-2 in sera of patients with breast and ovarian carcinoma.
    Mabrouk RA; Ali-Labib R
    Clin Biochem; 2003 Oct; 36(7):537-43. PubMed ID: 14563447
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Topoisomerase-II alpha expression as a predictive marker in a population of advanced breast cancer patients randomly treated either with single-agent doxorubicin or single-agent docetaxel.
    Durbecq V; Paesmans M; Cardoso F; Desmedt C; Di Leo A; Chan S; Friedrichs K; Pinter T; Van Belle S; Murray E; Bodrogi I; Walpole E; Lesperance B; Korec S; Crown J; Simmonds P; Perren TJ; Leroy JY; Rouas G; Sotiriou C; Piccart M; Larsimont D
    Mol Cancer Ther; 2004 Oct; 3(10):1207-14. PubMed ID: 15486187
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunohistochemical expression of topoisomerase II alpha and Her-2/neu in prostatic carcinoma and benign prostatic hyperplasia.
    Hasby EA; Saied EM
    J Egypt Natl Canc Inst; 2008 Jun; 20(2):158-67. PubMed ID: 20029472
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.